Anemia and Iron Management: Addressing Challenges and Generating Solutions.

ANNA Lunch Symposium - September 25, 2005
Minimizing the Implications of Iron-Deficiency Anemia With Appropriate Treatment.
Andrea Easom, MA, MNSC, APRN, BC, CNN
Successfully Managing Patient Outliers: A Case Study Analysis.
Vaughn Folkert, MD



Andrea Easom, MA, MNSC, APRN, BC, CNN
Instructor, College of Medicine
Family Nurse Practitioner
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Vaughn Folkert, MD
Director of Clinical Nephrology
Weiler Hospital of Albert Einstein College of Medicine
Associate Professor of Clinical Medicine
Albert Einstein College of Medicine
Bronx, New York
This satellite symposium is sponsored by an unrestricted educational grant from Watson Pharma, Inc. This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on September 25, 2005 at the American Nephrology Nurses' Association (ANNA) Annual Meeting in Las Vegas, Nevada. This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.
This activity has been awarded 1.5 contact hours by the American Nephrology Nurses Association (ANNA) which is accredited as a provider and approver of continuing education in nursing by the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA).
Posting Date: January 15, 2006
CE Credit Eligible Through: January 15, 2007
CE Credit Hours/Completion Time: 1.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.
LEARNING OBJECTIVES:
After participating in this program, the participant should be able to:
  1. Define serum ferritin and the current understanding of it in terms of safety and efficacy
  2. Review K/DOQI recommendations for treating patients based on serum ferritin levels
  3. Describe special concerns that exist in treating anemia in pediatric patients on dialysis
  4. Discuss dosing guidelines for administering IV iron in pediatric patients
  5. Evaluate the safety and efficacy of IV iron therapy
SPEAKER DISCLOSURE STATEMENT:
See individual talks.

SPONSORSHIP / SUPPORT :
This ANNA Satellite symposium was developed in conjunction with Fallon Medica, and the ANNA, and sponsored by a restricted educational grant from Watson Pharma, Inc.

ANNA and HDCN CE POLICY STATEMENTS:
The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.
 


BACK TO
TOPIC INDEX :